The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Massimo Cristofanilli, Jean-Yves Pierga, James Reuben, Alfred Rademaker, Andrew A Davis, Dieter J Peeters, Tanja Fehm, Franco Nole, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Mario Giuliano, Jose A Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Angela Fernandez de lascoiti, Leticia de Mattos-Arruda Show all
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | ELSEVIER SCIENCE INC | Published : 2019
BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease. METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meie..View full abstract
Lynn Sage Cancer Research Foundation.